ZNTL vs. ORKA, CMPS, AUTL, CYRX, CKPT, SNDL, TRDA, OLMA, ARCT, and HRTX
Should you be buying Zentalis Pharmaceuticals stock or one of its competitors? The main competitors of Zentalis Pharmaceuticals include Oruka Therapeutics (ORKA), COMPASS Pathways (CMPS), Autolus Therapeutics (AUTL), Cryoport (CYRX), Checkpoint Therapeutics (CKPT), SNDL (SNDL), Entrada Therapeutics (TRDA), Olema Pharmaceuticals (OLMA), Arcturus Therapeutics (ARCT), and Heron Therapeutics (HRTX). These companies are all part of the "pharmaceutical products" industry.
Zentalis Pharmaceuticals vs.
Zentalis Pharmaceuticals (NASDAQ:ZNTL) and Oruka Therapeutics (NASDAQ:ORKA) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their community ranking, valuation, institutional ownership, earnings, media sentiment, risk, profitability, analyst recommendations and dividends.
Zentalis Pharmaceuticals has a beta of 1.81, indicating that its stock price is 81% more volatile than the S&P 500. Comparatively, Oruka Therapeutics has a beta of 0.25, indicating that its stock price is 75% less volatile than the S&P 500.
Zentalis Pharmaceuticals received 45 more outperform votes than Oruka Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Oruka Therapeutics an outperform vote while only 61.76% of users gave Zentalis Pharmaceuticals an outperform vote.
Oruka Therapeutics has lower revenue, but higher earnings than Zentalis Pharmaceuticals. Oruka Therapeutics is trading at a lower price-to-earnings ratio than Zentalis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
In the previous week, Oruka Therapeutics had 7 more articles in the media than Zentalis Pharmaceuticals. MarketBeat recorded 21 mentions for Oruka Therapeutics and 14 mentions for Zentalis Pharmaceuticals. Zentalis Pharmaceuticals' average media sentiment score of 0.88 beat Oruka Therapeutics' score of 0.73 indicating that Zentalis Pharmaceuticals is being referred to more favorably in the media.
Zentalis Pharmaceuticals currently has a consensus price target of $8.24, suggesting a potential upside of 581.36%. Oruka Therapeutics has a consensus price target of $39.86, suggesting a potential upside of 276.72%. Given Zentalis Pharmaceuticals' higher probable upside, equities analysts plainly believe Zentalis Pharmaceuticals is more favorable than Oruka Therapeutics.
56.4% of Oruka Therapeutics shares are owned by institutional investors. 1.9% of Zentalis Pharmaceuticals shares are owned by insiders. Comparatively, 22.7% of Oruka Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Oruka Therapeutics' return on equity of -24.96% beat Zentalis Pharmaceuticals' return on equity.
Summary
Oruka Therapeutics beats Zentalis Pharmaceuticals on 10 of the 17 factors compared between the two stocks.
Get Zentalis Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for ZNTL and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Zentalis Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:ZNTL) was last updated on 5/22/2025 by MarketBeat.com Staff
Buy ZNTL Stock Free ZNTL Stock Alerts